<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E3436AFC-51A8-400A-B98A-2F29F0933745"><gtr:id>E3436AFC-51A8-400A-B98A-2F29F0933745</gtr:id><gtr:name>Capital Medical University</gtr:name><gtr:address><gtr:line1>8 Xitou Tiao</gtr:line1><gtr:line2>Touan men wai</gtr:line2><gtr:line3>FengTai District</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8F4D4E4F-055E-4A6B-B5A9-C73A9C2420A6"><gtr:id>8F4D4E4F-055E-4A6B-B5A9-C73A9C2420A6</gtr:id><gtr:name>Xinjiang Medical University</gtr:name><gtr:address><gtr:line1>Xinjiang Medical University</gtr:line1><gtr:line2>Xinyi Road 393</gtr:line2><gtr:line3>830011</gtr:line3><gtr:postCode>830011</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>RDM Investigative Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E3436AFC-51A8-400A-B98A-2F29F0933745"><gtr:id>E3436AFC-51A8-400A-B98A-2F29F0933745</gtr:id><gtr:name>Capital Medical University</gtr:name><gtr:address><gtr:line1>8 Xitou Tiao</gtr:line1><gtr:line2>Touan men wai</gtr:line2><gtr:line3>FengTai District</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8F4D4E4F-055E-4A6B-B5A9-C73A9C2420A6"><gtr:id>8F4D4E4F-055E-4A6B-B5A9-C73A9C2420A6</gtr:id><gtr:name>Xinjiang Medical University</gtr:name><gtr:address><gtr:line1>Xinjiang Medical University</gtr:line1><gtr:line2>Xinyi Road 393</gtr:line2><gtr:line3>830011</gtr:line3><gtr:postCode>830011</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EE698B07-6C45-47E9-A637-420AD61D5494"><gtr:id>EE698B07-6C45-47E9-A637-420AD61D5494</gtr:id><gtr:firstName>Tao</gtr:firstName><gtr:surname>Dong</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B3B7DA2A-9ABB-4DA4-BE3E-4D8A075D5323"><gtr:id>B3B7DA2A-9ABB-4DA4-BE3E-4D8A075D5323</gtr:id><gtr:firstName>Christian</gtr:firstName><gtr:surname>Eggeling</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/38C70F3F-2A52-4436-84FB-A9F91F073FF3"><gtr:id>38C70F3F-2A52-4436-84FB-A9F91F073FF3</gtr:id><gtr:firstName>Jan</gtr:firstName><gtr:surname>Rehwinkel</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FL018942%2F1"><gtr:id>5103FA74-9D35-47C1-9984-DBF6A8C642C3</gtr:id><gtr:title>The impact of IFTIM3 genetic variation on Influenza virus infection, immune responses and disease outcome</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L018942/1</gtr:grantReference><gtr:abstractText>Influenza is a global threat. The current avian influenza H7N9 outbreak in China has a high death rate and can transmit from human-to-human. In this study, we will explore how human genetic factors and immune responses influence the severity of the disease. We recently found that people with a particular genetic variant of a gene called IFITM3 are six times more likely to suffer from severe influenza infection than those without (Zhang et al, Nature Communications 2013). This variant gene is very rare in Northern European populations but is common in Chinese people. We found that in 69% of Chinese patients with severe pandemic influenza had only this variant form of IFITM3. This compares to 25% of healthy Chinese individuals. 

The IFITM3 protein inhibits the entry of influenza virus into cells; the variant is thought to be unable to do this. One key aim of our project will be to check whether this is true and if so why it lacks this function. If more viruses enter cells the disease may be more severe, but severe influenza is rare in China even though 25% of the population have only this variant of IFITM3. Therefore we suggest that there may be compensating genetic factors snd/or that strong immune responses in people with the variant of IFITM3 protect most of them from severe influenza. 

In this study therefore, we will look for other protective genes in Chinese people who have the susceptible IFITM3 gene but who do not get severe influenza. We will also examine their immune responses to the virus and compare those with immune responses to influenza virus in Chinese and UK people who do not carry this gene variant. We will focus particularly on innate immune responses, which are known to be highly active in severe influenza and may actually contribute to the problem. We will also study T cell immune responses, which are specific for the infecting virus and are normally important for rapid viral clearance. Our preliminary data suggest that these T cell responses are more active in Chinese people with the IFITM3 gene variant, which could help compensate for their increased genetic susceptibility to severe infection.

In this way we will gain a better picture of the risk of severe infection in Chinese people, conferred by this gene variant which is very common in the population. It is possible that increased genetic susceptibility in the Chinese helps the spread of influenza virus in South East Asia. We will examine this in the context of the new avian influenza H7N9 threat. We will ask whether this more aggressive virus can override the protection that the common (in Europeans) variant of IFITM3 offers and whether this version of the gene contributes to mild asymptomatic infection which we have previously shown to occur in seasonal, pandemic and avian influenza. Our special links to the infectious disease hospitals You'An and Ditan in Beijing make this unique study possible.

This study addresses important unsolved problems of influenza virus infection, taking a global rather than local view, which is clearly necessary to tackle this threat.</gtr:abstractText><gtr:technicalSummary>1. The effect of the C variant on IFITM3: virus entry and intracellular location.
We will employ optical microscopy including different fluorescent labeling approaches such as protein-specific antibodies or live-cell tagging technologies such as GFP or SNAP- and HALO-tags. Optical super-resolution microscopes (or nanoscopes), including the STED/RESOLFT or PALM/STORM technologies will enable us to explore the subtle changes in the spatial organization of IFITM3 between variants.

2. IFITM3 genotype impact on innate sensing of influenza A virus and virus entry. 
Primary fibroblasts will be grown from skin biopsies. Subsequently, these cells will be infected with IAV. The induction of chemokines and cytokines will be measured by ELISA, bioassays or RT Q-PCR. The accumulation of RIG-I stimulatory RNA in cells of different genotypes will be assessed by RNA extraction from infected cells and re-transfection into RIG-I reporter cells. JR has experience with this approach. In these experiments primary human cells will be used and complemented by human cell lines overexpressing or depleted of IFITM3, as well as IFITM3-deficient mouse fibroblasts.

3. Immune responses in IFITM3 CC/TT patients who do badly compared to those who do well.
a. Trascriptome profiles will be determined using Illumina Human HT-12 V3 Beadchip arrays, which contain more than 48,000 probes. A gene expression analysis software program, Genespring, version 7.1.3 (Agilent), will be used to perform statistical analysis, and hierarchical clustering of samples. A modular analysis strategy will be used as described, enabling the discrimination of clinical groups without reducing the dimensionality of the data. 
b. Detailed analysis of influenza specific T cell responses will be performed using overlapping peptides in the ELISPOT assay. In some cases, T cell line and clones will be grown and antiviral efficacy will be evaluated using target cells infected with different viral strains</gtr:technicalSummary><gtr:potentialImpactText>The likely beneficiaries of this research project will be patients, hospitals, the Health Protection Agency (UK) and the China Centre for Disease Control (China CDC). Vaccine manufacturers will also benefit. Most pandemics and epidemics have originated in South East Asia where farming practices, bird migration patterns and possibly local genetics (the subject of this proposal) may contribute. As influenza, once spreading in humans, rapidly reaches all parts of the world, these factors will impact on the UK. The findings of the proposed study will be important to China and UK residents of Chinese descent if they show that the human genetic factor IFITM3 influences the immune responses to the epidemic, pandemic and novel avian viruses, and consequently the severity of the disease.

Our primary hypothesis is that the risk of severe disease in people with IFITM3 CC genotype can be offset by other genetic factors and/or by improved immune responses. Despite of this, there might be higher incidences of severe influenza in Chinese patients, possibly up to six-fold increase. Furthermore, we hypothesise that subclinical infection will more common in people with the IFITM3 TT genotype, consequently subclinical cases will occur more frequently in the UK than in China. However the influence of the IFTIM3 gene might be different for a virulent avian virus such as the H7N9 virus and this will be determined in this study. Thus we will better understand the factors contributing to disease severity. IFITM3 genotype screening could be utilized for prognosis and guiding early intensification of treatments. Moreover, If the CC genotype carriers possess stronger immune responses, as we propose, they could be prioritised for vaccination. These studies could provide us with crucial information to improve the current vaccine strategies and therapy in different target populations such as in UK and China. Hence, our proposed research could prominently improve quality of life by controlling and preventing life-threatening influenza illness.

The study may also have relevance to vaccination planning. Currently live attenuated vaccines are being given to children. As a live virus vaccine, the IFITM3 genotype could influence the take rate of this vaccine and possibly the incidence of side effects. This is not being tested in this study but once we know more about the role of IFITM3 in influenza virus infection, this could be an important follow on study that would have an important impact on medical practice. 

Lastly this study will be a strong UK - China collaboration with significant scientific contributions from both sides. The lead investigator is a Chinese but resident in the UK. She has an honorary joint appointment at the You'an Hospital, Capital University, Beijing and holds grants from Nature Science Foundation China for major international collaboration and is collaborator/partners on many others such as Chinese Ministry of Science and Technology funding for Major International collaboration. The project is covered by a Memorandum of Understanding between the MRC and Beijing Bureu of Science and Tachnology(NJSTB), signed in 2007 by sir Andrew McMichal on behalf of MRC and Director of NJSTB; and between Beijing You'an hospital(BJYA) and MRC Human Immunology Unit(HIU), in 2012 signed by Director HIU Vincenzo Cerundolo and the Director Li of BJYA. Given the importance of influenza, the threat of new pandemics often arising in South East Asia, these very strong links will give the MRC a very strong role in working with China to combat current and future influenza threats. This partnership could be extended to other infectious disease threats, such as a recurrence of SARS, should they arise.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-06-30</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>886107</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Capital University of Medical Sciences</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Mapping HBV epitopes</gtr:description><gtr:id>7E611381-D76C-4F57-9902-40974185E3EA</gtr:id><gtr:impact>not yet</gtr:impact><gtr:partnerContribution>Grant from Minister of Science and technology, Youan hospital internal funds for patient recruitment, and immunology core facility, consumables (total CNY 5000000)</gtr:partnerContribution><gtr:piContribution>Grant from Janssen pharmaceutical (1000000USD) and MRC HIU core support</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Capital University of Medical Sciences</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Youan Infectious Diseases Hospital</gtr:department><gtr:description>Influenza specific T cell responses in influenza virus infection in China</gtr:description><gtr:id>10D25A58-27D2-4F7E-945F-D4FD66420A23</gtr:id><gtr:impact>paper in preparation</gtr:impact><gtr:partnerContribution>Performed large part of the experiments</gtr:partnerContribution><gtr:piContribution>Direct the study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Edward Jenner Institute for Vaccine Research</gtr:department><gtr:description>Flu vaccine for heterosubtypeic protection</gtr:description><gtr:id>A1C6376B-CE62-4530-A321-4ADF8B677E7F</gtr:id><gtr:impact>2 paper submitted</gtr:impact><gtr:partnerContribution>Access to patient cohort after flu challenge, enable us to study the role of pre-existing T cells in contributing to the protection and disease outcome.</gtr:partnerContribution><gtr:piContribution>Expertise in T cell study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xinjiang Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>TAA specific T cell responses in cancer patients</gtr:description><gtr:id>64FD4340-ED1C-454F-8884-F5A64638B46A</gtr:id><gtr:impact>One paper published on HLA association with EBV associated NPC (Immunology 2014), more to come. Joint funding from NSFC, Minister of Science and Technology China and MRC HIU core)</gtr:impact><gtr:partnerContribution>Joint grant application, patient recruitment, blood nab samples, local technique support, local ethic applications etc.</gtr:partnerContribution><gtr:piContribution>Design and performed experiments, wrote research proposal together, training local researchers</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Oxford High School Visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C4EEF7F0-1249-47B8-B768-0994F2BBEAE2</gtr:id><gtr:impact>Talk on HIV and AIDS in Africa

The talk heightened the understanding of HIV and AIDS</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at Plymouth University about PhD life and Career Options</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>923E5BE8-BEAD-408D-B561-135ABE89BE81</gtr:id><gtr:impact>Dr Dannielle Wellington, part of Professor Dong'd group have a talk to Plymouth University undergraduate students about PhD life and career options in a Q &amp;amp; A session.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2014,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gene responsible for increased severity of influenza in Chinese populations, published online in the MRC network magazine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2D945A85-6D23-4009-9B0F-93C6277FBC6C</gtr:id><gtr:impact>n/a</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.mrc.ac.uk/news-events/news/gene-responsible-for-increased-severity-of-influenza-in-chinese-populations/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gene linked to more severe flu in Chinese populations</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FDE25D31-574A-4EE6-A21A-0896DEB3B25B</gtr:id><gtr:impact>Online news segment explaining the genetic variant which explains why Chinese populations may be more vulnerable to H1N1 swine flu has been found by researchers at the University of Oxford and Beijing Capital Medical University.

n/a</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ox.ac.uk/news/2013-01-29-gene-linked-more-severe-flu-chinese-populations</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Beijing-UK Emerging Infectious Disease symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1615BD1C-E6CD-4F10-9238-E2E90D1ED246</gtr:id><gtr:impact>Talks between Beijing and UK delegates sparked talks and discussions afterwards.

Talks encouraged more collaborations between Beijing and UK.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>workshop facilitator</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Podcast on University Website</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0BF673ED-C594-4FB0-A53B-CF1B30F2D7BE</gtr:id><gtr:impact>A podcast on Infectious diseases in China

n/a</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ndm.ox.ac.uk/tao-dong-infectious-diseases-in-china</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lab tour for Dutch college students</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BC15499C-5535-4C76-857C-0191CAEF2596</gtr:id><gtr:impact>Dr Dannielle Wellington, part of Prof. Dong's group conducted a lab tour for Dutch college students and answered their questions about career and University</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Women in Science Interview, posted online</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>41529E46-54EC-497B-A688-814216318990</gtr:id><gtr:impact>A project on 'Experiences of Women in Science at the University of Oxford'. It has been funded by the Vice-Chancellor's Diversity Fund. One of the primary aims of the new Fund is to address the under-representation of women in senior research and academic posts. The aim of this project is to develop a University of Oxford website based on interviews with women scientists at different stages of their careers.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk for World AIDS DAY 2014, St Edmund Hall</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>10FC9B5B-6D01-4F2E-8950-CC238082A9C6</gtr:id><gtr:impact>Ms Sophie Andrews who Professor Dong is a supervisor of did a talk which sparked questions and discussion afterwards.

n/a</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Festival of Science</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0BE5A956-C3CD-4E79-B3E1-D49D737F531D</gtr:id><gtr:impact>Kerry Kite, Research Assistant in Prof. Dong's group took part in the MRC Festival of Science. The aim was to interact with the public outside a local supermarket in Whitney. We wanted to explain the work the MRC does involving genetically engineering viruses to kill cancerous cells. The impact was to show the public, who's tax money goes towards our funding, our work and explain it to them in a way they can understand. We spoke to children, teenagers and adults of various backgrounds. They played games and won chocolates and freebies as well as the chance to ask many questions and discuss other areas of science they were interested in.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Janssen Pharmaceutical - Characterising HBV specific T cells in HBV associated liver disease</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Janssen Biotech</gtr:fundingOrg><gtr:id>5E3C37FC-39CE-42E0-9988-8AFB6D58E7FB</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>523348</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European FP7,EU FP7-HEALTH-2012-INNOVATION</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>3D6912AA-D920-4DAD-9C67-9ED5E8C4BD6C</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1107634</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Research Grant</gtr:department><gtr:description>The impact of IFTIM3 genetic variation on influenza virus infection, immune responses and disease outcome</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A5943382-2620-48CD-B3C8-CA40C3181DF5</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>213422</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Institutional Strategic Support Fund (WTISSF) , T-Cell Immunity to HBV associated HCC</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>70AB529D-92E4-43E5-BF64-862251BE2B9B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>987001</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Research Grant</gtr:department><gtr:description>The use of human monoclonal antibodies to inform and enhance influenza vaccine virus selection</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7E0443B8-F817-41C3-89E0-8FDF91C0FAE9</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4000000</gtr:amountPounds><gtr:country>China, People's Republic of</gtr:country><gtr:currCode>CNY</gtr:currCode><gtr:currCountryCode>China</gtr:currCountryCode><gtr:currLang>zh_CN</gtr:currLang><gtr:description>Immune responses in HBV associated HCC (Overseas co-applicant)</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Ministry of Science and Technology (MOST)</gtr:fundingOrg><gtr:id>6B8D681A-CC3C-46C9-8565-E5A399B9D7BC</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>China, People's Republic of</gtr:country><gtr:currCode>CNY</gtr:currCode><gtr:currCountryCode>China</gtr:currCountryCode><gtr:currLang>zh_CN</gtr:currLang><gtr:description>Anti-viral T cells in HIV infection</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>National Science Foundation China</gtr:fundingOrg><gtr:id>40667352-56F0-47EA-BF2D-B21C830797A7</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>813590</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Human Immunology Unit = program title: Human Anti-viral T cells (1 of 10 groups in HIU)</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9484ECA4-AB5E-4C5B-88C6-8D8F58CB82E9</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1477000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Human Immunology Unit</gtr:department><gtr:description>Human Anti-viral T Cells</gtr:description><gtr:end>2022-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3039EE31-AE79-42DB-8F6D-A131E68B31DE</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2800000</gtr:amountPounds><gtr:country>China, People's Republic of</gtr:country><gtr:currCode>CNY</gtr:currCode><gtr:currCountryCode>China</gtr:currCountryCode><gtr:currLang>zh_CN</gtr:currLang><gtr:description>The Impact of IFITM3 variants in influenza virus infection</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>National Science Foundation China</gtr:fundingOrg><gtr:id>7228AEFB-1080-49F3-A593-B54CE5353259</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Flu vaccine for heterosubtypeic protection</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>5B31EA82-6703-4971-8CD5-D7B8C0F408B1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Janssen Pharmaceutical - Characterising HBV specific T cells in HBV associated liver disease</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Janssen Biotech</gtr:fundingOrg><gtr:id>75741324-6638-4AD4-AE05-EF63B88B7E54</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2800000</gtr:amountPounds><gtr:country>China, People's Republic of</gtr:country><gtr:currCode>CNY</gtr:currCode><gtr:currCountryCode>China</gtr:currCountryCode><gtr:currLang>zh_CN</gtr:currLang><gtr:description>Studying the Tumour specific T cells in virus associated cancer</gtr:description><gtr:end>2022-04-02</gtr:end><gtr:fundingOrg>National Science Foundation China</gtr:fundingOrg><gtr:id>AC70A49F-3C6D-4C52-B634-090C888322F3</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC capacity building studentships (Srinika Ranasinghe)</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E53579AD-B509-455B-87D7-3246C62518A1</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2005-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1800000</gtr:amountPounds><gtr:country>Canada</gtr:country><gtr:currCode>CAD</gtr:currCode><gtr:currCountryCode>Canada</gtr:currCountryCode><gtr:currLang>en_CA</gtr:currLang><gtr:description>Developing Research Capacity for West African Network for Prevention Trials</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Global Health Research Initiative (GHRI)</gtr:fundingOrg><gtr:id>AE59D11F-6A0D-4F78-A19E-9A0B612E7BBD</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>412500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant: T cell in H5N1 infection</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>135D5A62-8FD1-4FAB-ACF9-C2D227790EBB</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Health and Medical Research Fund, peer review for funding agencies</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>93B96DE7-E5BA-491F-AFA4-D3940E583D9F</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Peer review for funding agencies, Skokovo Foundation, Moscow, Russia</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>43C13F1F-B935-47E5-B565-9A0F5581D800</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Peer review for Medical Research Council</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>822CEC90-90D6-40F2-81A2-EB7E3E077550</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Peer review for funding agencies, Research Grants Council (RGC)</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>6E2889D2-DC6A-4B53-A877-2AFE83FAD7B1</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Peer review for funding agencies, Natural Science Foundation (ANR)</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>881DD9F9-0D7A-4FBE-95B3-A4CAB56C16EA</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Peer review for funding agencies, The University of Washington Fred Hutchingson Cancer Research Centre AIDS Research (NIAID) program</gtr:description><gtr:geographicReach>South America</gtr:geographicReach><gtr:id>A67F5C00-3FE2-41EE-B8CB-8988962AE25B</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Peptide containing new T cell epitopes, overlapping peptides spanning H5N1, and human H3N2 proteome</gtr:description><gtr:id>B20EA1DD-E8C7-4946-9FC3-5D82E778E4C1</gtr:id><gtr:impact>Cross reactive peptides could be used for study the impact of cross reactive T cell responses in Vaccine trails and human influenza infected patients.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>T cell epitopes and overlapping peptides</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD409119-9429-4A99-A1B1-4D871DA2DA74"><gtr:id>AD409119-9429-4A99-A1B1-4D871DA2DA74</gtr:id><gtr:title>Boosted Influenza-Specific T Cell Responses after H5N1 Pandemic Live Attenuated Influenza Virus Vaccination.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0bccd0fd70584179d048b43693c7805b"><gtr:id>0bccd0fd70584179d048b43693c7805b</gtr:id><gtr:otherNames>Peng Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ECE183B0-DDA7-4945-9972-03C6507F1D6A"><gtr:id>ECE183B0-DDA7-4945-9972-03C6507F1D6A</gtr:id><gtr:title>Detection of a novel killer-cell immunoglobulin-like receptor allele&amp;nbsp;-&amp;nbsp;KIR3DL1*0150207&amp;nbsp;-&amp;nbsp;in Asian individuals.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c4fb28c7b7f759ed5da54d4f587d639a"><gtr:id>c4fb28c7b7f759ed5da54d4f587d639a</gtr:id><gtr:otherNames>Wang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/27B50EE7-9752-42CF-B8C7-727832BDC10D"><gtr:id>27B50EE7-9752-42CF-B8C7-727832BDC10D</gtr:id><gtr:title>Killer-cell immunoglobulin-like receptor gene 3DL1*077 isolated using long-range sequence-based techniques.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1585CD16-9F37-4CE9-B6A7-20E96D18821C"><gtr:id>1585CD16-9F37-4CE9-B6A7-20E96D18821C</gtr:id><gtr:title>HLA-A*02-B*46 haplotype: an adverse prognostic factor in Han patients with nasopharyngeal carcinoma.</gtr:title><gtr:parentPublicationTitle>Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2d9f7df13cab6b06033afc0291664407"><gtr:id>2d9f7df13cab6b06033afc0291664407</gtr:id><gtr:otherNames>Wang RZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1672-0733</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9027CA4-2D87-4205-9415-DE9A2A18DF4A"><gtr:id>C9027CA4-2D87-4205-9415-DE9A2A18DF4A</gtr:id><gtr:title>Multiple T-cell responses are associated with better control of acute HIV-1 infection: An observational study.</gtr:title><gtr:parentPublicationTitle>Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fbee13de0f083ea68ae008d704b0ddd"><gtr:id>3fbee13de0f083ea68ae008d704b0ddd</gtr:id><gtr:otherNames>Sun J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0025-7974</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D82726B9-BA2A-4CA6-A905-BD505007873E"><gtr:id>D82726B9-BA2A-4CA6-A905-BD505007873E</gtr:id><gtr:title>Interferon-induced transmembrane protein-3 rs12252-C is associated with rapid progression of acute HIV-1 infection in Chinese MSM cohort.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d895db59e431e55ec84105d0da4fab0d"><gtr:id>d895db59e431e55ec84105d0da4fab0d</gtr:id><gtr:otherNames>Zhang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D4B6B6CB-27E0-4A67-BD15-44D9E453E7B0"><gtr:id>D4B6B6CB-27E0-4A67-BD15-44D9E453E7B0</gtr:id><gtr:title>The KIR3DS1*0130105 allele identified using high-resolution sequence-based typing.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/64268A14-5C51-4859-9D31-22C1E2E32F2E"><gtr:id>64268A14-5C51-4859-9D31-22C1E2E32F2E</gtr:id><gtr:title>Description of a novel KIR3DL1*0050104 allele identified using sequence-based techniques.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/084C7F13-A3C9-471F-BCD7-49B6C500AAF3"><gtr:id>084C7F13-A3C9-471F-BCD7-49B6C500AAF3</gtr:id><gtr:title>Dominant CD4-dependent RNA-dependent RNA polymerase-specific T-cell responses in children acutely infected with human enterovirus 71 and healthy adult controls.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eaa9f13165e076c2f67773a1f8ff7fd5"><gtr:id>eaa9f13165e076c2f67773a1f8ff7fd5</gtr:id><gtr:otherNames>Dang S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D44C13E7-5ACF-4135-A634-C3F72AF15248"><gtr:id>D44C13E7-5ACF-4135-A634-C3F72AF15248</gtr:id><gtr:title>Identification of KIR3DL1*0150208 using long-range sequence-based techniques.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c4fb28c7b7f759ed5da54d4f587d639a"><gtr:id>c4fb28c7b7f759ed5da54d4f587d639a</gtr:id><gtr:otherNames>Wang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DED7C828-8B49-4873-9735-181500C96D29"><gtr:id>DED7C828-8B49-4873-9735-181500C96D29</gtr:id><gtr:title>Identification of KIR3DL1*0200101 by long-range sequence-based techniques.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7EF514F4-0713-47BD-A289-DFF45B29ED52"><gtr:id>7EF514F4-0713-47BD-A289-DFF45B29ED52</gtr:id><gtr:title>Full-length genomic sequence of a new KIR3DL1*0150203 allele.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3EAE27B9-5A7F-4BA7-976F-6E8AA3FF352D"><gtr:id>3EAE27B9-5A7F-4BA7-976F-6E8AA3FF352D</gtr:id><gtr:title>A statistical approach to determining responses to individual peptides from pooled-peptide ELISpot data.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/16b26d8a504fa824577d7c9a7ea4c286"><gtr:id>16b26d8a504fa824577d7c9a7ea4c286</gtr:id><gtr:otherNames>Str?m P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2F71667C-1211-463E-82AE-A245B1871612"><gtr:id>2F71667C-1211-463E-82AE-A245B1871612</gtr:id><gtr:title>A novel KIR3DS1*0130107 allele isolated by sequencing from an Asian donor.</gtr:title><gtr:parentPublicationTitle>International journal of immunogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1744-3121</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A4884822-2441-4967-949F-47BF4EDF5415"><gtr:id>A4884822-2441-4967-949F-47BF4EDF5415</gtr:id><gtr:title>The presence of prolines in the flanking region of an immunodominant HIV-2 gag epitope influences the quality and quantity of the epitope generated.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7ecf15dad4439b15c78ef2845f4adcd3"><gtr:id>7ecf15dad4439b15c78ef2845f4adcd3</gtr:id><gtr:otherNames>Jallow S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/50CAC4D7-804C-43A9-9108-EFEBDFC170A5"><gtr:id>50CAC4D7-804C-43A9-9108-EFEBDFC170A5</gtr:id><gtr:title>Multilayered HIV-1 gag-specific T-cell responses contribute to slow progression in HLA-A*30-B*13-C*06-positive patients.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1bde23452702f3d087e5f35cb87dd0e1"><gtr:id>1bde23452702f3d087e5f35cb87dd0e1</gtr:id><gtr:otherNames>Zhang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/64D90CBF-0271-4E2B-9DE7-F6F46AFA74B9"><gtr:id>64D90CBF-0271-4E2B-9DE7-F6F46AFA74B9</gtr:id><gtr:title>Long-range sequencing revealed a new KIR3DL1*0150204 allele in 20 individuals of Asian descent.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/023B27AE-59E0-42C4-8A38-60109E544AA5"><gtr:id>023B27AE-59E0-42C4-8A38-60109E544AA5</gtr:id><gtr:title>Report of a novel activating killer-cell immunoglobulin-like receptor allele 3DS1*078 identified using sequence-based typing.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C1EF94D-5A85-4054-8BF0-A7DF8B901A1B"><gtr:id>3C1EF94D-5A85-4054-8BF0-A7DF8B901A1B</gtr:id><gtr:title>Detection of a novel KIR3DL1*0150210 allele by sequencing.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c4fb28c7b7f759ed5da54d4f587d639a"><gtr:id>c4fb28c7b7f759ed5da54d4f587d639a</gtr:id><gtr:otherNames>Wang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/009F336D-BE0A-422A-B2D5-04CD271E5790"><gtr:id>009F336D-BE0A-422A-B2D5-04CD271E5790</gtr:id><gtr:title>A novel KIR3DL1*0070104 allele found in individuals from Asia.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF1C6CBB-9C76-4B8E-9953-0123D0AD5C83"><gtr:id>CF1C6CBB-9C76-4B8E-9953-0123D0AD5C83</gtr:id><gtr:title>A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3d0c6b9b627239f85e603ce8f8de6ade"><gtr:id>3d0c6b9b627239f85e603ce8f8de6ade</gtr:id><gtr:otherNames>Zhang YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2380F2FE-DB64-4250-83BD-49E6536A999E"><gtr:id>2380F2FE-DB64-4250-83BD-49E6536A999E</gtr:id><gtr:title>Full length KIR3DS1*0130110 allele isolated by SBT.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/208C12DF-19CA-43A2-B3DD-37D7F107729C"><gtr:id>208C12DF-19CA-43A2-B3DD-37D7F107729C</gtr:id><gtr:title>Critical role of endoplasmic reticulum aminopeptidase 1 in determining the length and sequence of peptides bound and presented by HLA-B27.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fbfd9fb6e692d07596464ca94848bf67"><gtr:id>fbfd9fb6e692d07596464ca94848bf67</gtr:id><gtr:otherNames>Chen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF217A2F-B6DB-40E5-A9FF-D40B664C9855"><gtr:id>CF217A2F-B6DB-40E5-A9FF-D40B664C9855</gtr:id><gtr:title>Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/51f09ae31d36a289662577675db5ec78"><gtr:id>51f09ae31d36a289662577675db5ec78</gtr:id><gtr:otherNames>Jayasooriya S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D8803C7-B9E8-4BAA-B36B-78699A613449"><gtr:id>5D8803C7-B9E8-4BAA-B36B-78699A613449</gtr:id><gtr:title>Combinatorial HLA-peptide bead libraries for high throughput identification of CD8? T cell specificity.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fa6b6c24080c1135d3653d8e343c7a89"><gtr:id>fa6b6c24080c1135d3653d8e343c7a89</gtr:id><gtr:otherNames>Pan X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BAE4D247-75E9-40CB-A5F9-AAAA989EE6C9"><gtr:id>BAE4D247-75E9-40CB-A5F9-AAAA989EE6C9</gtr:id><gtr:title>Multi-layered Gag-specific immunodominant responses contribute to improved viral control in the CRF01_AE subtype of HIV-1-infected MSM subjects.</gtr:title><gtr:parentPublicationTitle>BMC immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d6a9149bbfa93ced1ec129cdcdfb0084"><gtr:id>d6a9149bbfa93ced1ec129cdcdfb0084</gtr:id><gtr:otherNames>Jiang F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2172</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/77177087-8505-4165-A205-FE010C8B5BDB"><gtr:id>77177087-8505-4165-A205-FE010C8B5BDB</gtr:id><gtr:title>The identification of a killer cell immunoglobulin-like receptor 3DL1*0150209 in an Asian population using molecular techniques.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2BEC1598-B325-47B7-A53F-7B8A2321B6D5"><gtr:id>2BEC1598-B325-47B7-A53F-7B8A2321B6D5</gtr:id><gtr:title>Viruses transfer the antiviral second messenger cGAMP between cells.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e491ba8e5b16c64ec3cb8b381ebef5a"><gtr:id>3e491ba8e5b16c64ec3cb8b381ebef5a</gtr:id><gtr:otherNames>Bridgeman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B63C6AE6-350B-4939-A61A-90D80A37E06D"><gtr:id>B63C6AE6-350B-4939-A61A-90D80A37E06D</gtr:id><gtr:title>Association analysis between HLA-A, -B, -C, -DRB1, and -DQB1 with nasopharyngeal carcinoma among a Han population in Northwestern China.</gtr:title><gtr:parentPublicationTitle>Human immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/17f6633e9d8a0b4804343fbc2df4165c"><gtr:id>17f6633e9d8a0b4804343fbc2df4165c</gtr:id><gtr:otherNames>Wang R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0198-8859</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/74DBD84E-8E5A-4D60-9E23-C218EBB22D2B"><gtr:id>74DBD84E-8E5A-4D60-9E23-C218EBB22D2B</gtr:id><gtr:title>Report of a novel KIR3DS1*0130104 allele discovered using advanced molecular techniques.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D5B77D1A-3A33-488C-A1AC-4C0014FE3469"><gtr:id>D5B77D1A-3A33-488C-A1AC-4C0014FE3469</gtr:id><gtr:title>Two novel KIR3DL1 alleles, 3DL1*0150205 and 3DL1*0150206, identified by full-length DNA sequencing.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F5816D55-1497-48E1-83AA-14CBC08D357F"><gtr:id>F5816D55-1497-48E1-83AA-14CBC08D357F</gtr:id><gtr:title>KIR3DS1*0130108 isolated using full length sequence-based typing.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bff4ee4ff81e130304b8d75404a55387"><gtr:id>bff4ee4ff81e130304b8d75404a55387</gtr:id><gtr:otherNames>Yindom LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C82BF4CB-7842-4606-9C32-915A0565980E"><gtr:id>C82BF4CB-7842-4606-9C32-915A0565980E</gtr:id><gtr:title>Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07fefc16726e8220ca1003792597d1ee"><gtr:id>07fefc16726e8220ca1003792597d1ee</gtr:id><gtr:otherNames>Nakaya HI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/34A9367E-8C5B-4133-9BCF-193E96A12B8D"><gtr:id>34A9367E-8C5B-4133-9BCF-193E96A12B8D</gtr:id><gtr:title>Identification of the KIR3DL1*0050105 allele by sequence-based techniques.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c4fb28c7b7f759ed5da54d4f587d639a"><gtr:id>c4fb28c7b7f759ed5da54d4f587d639a</gtr:id><gtr:otherNames>Wang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/307F5094-36A0-4F2C-97DE-7EDDA455CC5B"><gtr:id>307F5094-36A0-4F2C-97DE-7EDDA455CC5B</gtr:id><gtr:title>A novel full-length KIR3DS1*0130106 allele identified by sequencing.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c4fb28c7b7f759ed5da54d4f587d639a"><gtr:id>c4fb28c7b7f759ed5da54d4f587d639a</gtr:id><gtr:otherNames>Wang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1AE39442-1F74-42D9-A40B-9E365CD52086"><gtr:id>1AE39442-1F74-42D9-A40B-9E365CD52086</gtr:id><gtr:title>CD8+ cytotoxic T lymphocytes in human influenza virus infection.</gtr:title><gtr:parentPublicationTitle>National science review</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c22f4dff265ae6494e8c07966c893b13"><gtr:id>c22f4dff265ae6494e8c07966c893b13</gtr:id><gtr:otherNames>Dong T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2053-714X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L018942/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>